1. Inicio
  2. Publicaciones
  3. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Balana C
  • Vaz MA
  • Sepúlveda JM
  • Mesia C
  • Del Barco S
  • Pineda E
  • Estival A
  • de Las Peñas R
  • Fuster J
  • Navarro LM
  • Gil-Gil M
  • Alonso M
  • Herrero A
  • Peralta S
  • Olier C
  • Perez-Segura P
  • Covela M
  • Martinez-García M
  • Berrocal A
  • Gallego O
  • Luque R
  • Perez-Martín FJ
  • Esteve A
  • Munne N
  • Domenech M
  • Villa S
  • Sanz C
  • Carrato C

Abstract

Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for six cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized, trial investigating whether extending adjuvant temozolomide for more than six cycles improved outcome.

Datos de la publicación

ISSN/ISSNe:
1522-8517, 1523-5866

NEURO-ONCOLOGY  OXFORD UNIV PRESS INC

Tipo:
Article
Páginas:
1851-1861
PubMed:
32328662
Factor de Impacto:
4,005 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 83

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • MGMT methylation, extended adjuvant temozolomide, glioblastoma, prognosis

Campos de Estudio

Compartir